This is an author produced version of a paper published in:
*Value in Health*

Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa24715

**Paper:**

http://dx.doi.org/10.1016/j.jval.2015.09.2389

This article is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms of the repository licence. Authors are personally responsible for adhering to publisher restrictions or conditions. When uploading content they are required to comply with their publisher agreement and the SHERPA RoMEO database to judge whether or not it is copyright safe to add this version of the paper to this repository.

http://www.swansea.ac.uk/iss/researchsupport/cronfa-support/
Abstract: 300 words

**Title:** How are pain treatment response rates in primary care influenced by co-prescription of CYP2D6 inhibitors?

**Authors:** Rhys Pockett, Caroline O’Leary, Pippa Anderson, Ahmed Nasser, Thomas Winfield, David Ansell

**Objectives:** To determine the rates of co-prescription of CYP2D6-inhibiting medications with pain medication and the impact on response rates to pain medications, in the UK primary care setting.

**Methods:** Codeine and tramadol are prodrugs requiring activation by the CYP2D6 enzyme. These drugs may have limited effectiveness when co-prescribed with other medications known to inhibit the CYP2D6 pathway. This contrasts with CYP2D6-independent analgesia, e.g. buprenorphine, which do not require CYP2D6 activation.

We identified the co-prescription of three study pain medications; buprenorphine, codeine and tramadol with CYP2D6-inhibiting drugs including amitriptyline and fluoxetine. Patients aged ≥18 years with chronic non-malignant pain and prescribed buprenorphine, codeine or tramadol between 01/01/2009 and 31/01/2013 were identified in The Health Improvement Network (THIN) database. Patients were excluded if they had history of; chronic kidney disease stage 4/5, cancer, neuropathic pain, sciatica/radiculopathy, diabetes, back pain or a prior prescription for a study drug. Patients were classified as responders if they were either “cured” (discontinued treatment) or stable (remained on treatment), or a non-responder if they were referred to a pain clinic or switched to a CYP2D6-independent analgesic. Multivariate logistic regression was used to identify the predictors of response and estimate the influence of CYP2D6-inhibitors.

**Results:** The cohort consisted of 43,632 patients: 90.8% were responders, and CYP2D6-inhibiting drugs were prescribed to 33.8% of the cohort. Almost three times as many patients failed to respond in those prescribed a CYP2D6-inhibitor (16% vs. 6%). Controlling for medication, demographics and co-morbidities the logistic regression indicated the odds of responding for those with a CYP2D6-inhibiting co-prescription were 39% lower than those without a co-prescription for a CYP2D6 inhibiting drug (OR= 0.61, 95% CI 0.57 to 0.66).

**Conclusion:** Chronic non-malignant pain patients with a co-prescription for a CYP2D6-inhibiting medication were significantly less likely to respond to analgesia treatment and therefore received suboptimal pain management.